News from hansa biopharma ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 24, 2020, 14:24 ET Hansa Biopharm announces positive high-level data from investigator-initiated phase 2 trial with imlifidase to treat anti-GBM disease

Hansa Biopharma ("Hansa"), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces positive high-level data...


Sep 17, 2020, 02:48 ET Hansa Biopharma to host Capital Markets Day on Thursday October 29, 2020 in Copenhagen

Hansa Biopharma ("Hansa"), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company will...


Sep 01, 2020, 13:59 ET Hansa Biopharma provides updated guidance on its clinical programs

Hansa Biopharma ("Hansa"), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced updated guidance...


Aug 31, 2020, 02:12 ET Hansa Biopharma announces participation in Fall conferences and an updated financial calendar

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team...


Aug 26, 2020, 14:13 ET The EU Commission grants conditional approval for IdefirixTM (imlifidase) in highly sensitized kidney transplant patients in the European Union

Hansa Biopharma ("Hansa"), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the European...


Jul 31, 2020, 11:44 ET Hansa Biopharma announces increase in number of shares and votes

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces that the Company' s registered...


Jul 16, 2020, 02:20 ET Hansa Biopharma Interim Report Jan-Jun 2020

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim...


Jul 02, 2020, 01:56 ET Hansa Biopharma Announces Exclusive Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy in Select Indications

Hansa Biopharma ("Hansa"), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, announced today that it has entered into...


Jun 30, 2020, 02:22 ET Hansa Biopharma to Host Conference Call to Provide Interim Results for the First Half of 2020 and Business Update

Hansa Biopharma will publish its interim report for January-June 2020 at 8:00 a.m. CET on July 16, 2020. All interested parties are invited to...


Jun 25, 2020, 11:43 ET Hansa Biopharma Receives Positive CHMP Opinion for IdefirixTM (imlifidase) for Kidney Transplant in EU

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Committee for Medicinal...


Jun 23, 2020, 10:46 ET Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)

Resolution regarding the adoption of the income statement and the balance sheet as well as consolidated income statement and consolidated balance...


May 29, 2020, 02:53 ET Hansa Biopharma Appoints Achim Kaufhold as CMO to Support the Expansion Outside Transplantation

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company has appointed...


May 25, 2020, 03:25 ET Hansa Biopharma Submits Responses to Outstanding Questions From EMA on May 26

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the ongoing EMA review of...


May 20, 2020, 03:29 ET Notice to Annual General Meeting in Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, summons to Annual General Meeting on Tuesday June 23, 2020 at 15:00...


May 20, 2020, 02:22 ET Hansa Biopharma Announces Upcoming Presentations Including a Late Breaking Poster Presentation at the 2020 American Transplant Congress

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's novel...


May 13, 2020, 02:34 ET Hansa Biopharma to Participate in Five Upcoming Investor Conferences During May and June

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team...


Apr 28, 2020, 02:27 ET Hansa Biopharma Interim Report Jan-Mar 2020. EMA Process on Track; an Opinion From the CHMP is Expected in the Second Quarter 2020

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim...


Apr 15, 2020, 02:16 ET Hansa Biopharma to Host Conference Call to Provide Interim Results for the First Quarter of 2020 and Business Update

Hansa Biopharma will publish its interim report for January-March 2020 at 8:00 a.m. CET on April 28, 2020. All interested parties are invited to...


Apr 02, 2020, 02:11 ET Hansa Biopharma Publishes Annual Report 2019

Søren Tulstrup, President and CEO of Hansa Biopharma, comments: "2019 was an important and overall successful year for Hansa Biopharma - a year with...


Mar 06, 2020, 02:25 ET Hansa Biopharma Announces Long Term Follow-up Data That Demonstrates 2-year Graft Survival of 89% After Imlifdase Treatment and Transplantation

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases today announced that two posters sessions were...


Feb 25, 2020, 02:19 ET Hansa Biopharma to Participate in Two Upcoming Investor Conferences

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team...


Feb 06, 2020, 02:20 ET Hansa Biopharma Year-End Report 2019

Highlights for the fourth quarter 2019 The ongoing review of an MAA for imlifidase in Europe by EMA is on track. Responses to the Day 120 questions...


Jan 27, 2020, 02:31 ET Hansa Biopharma Completes Enrollment in Anti-GBM

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the patient enrollment in an...


Jan 22, 2020, 02:20 ET Hansa Biopharma to Host Conference Call to Provide Year-End report 2019 and Business Update

Hansa Biopharma will publish its Year-End report 2019 at 8:00 a.m. CET on February 6, 2020. All interested parties are invited to participate in a...


Jan 12, 2020, 21:54 ET Hansa Biopharma Provides Business Update Ahead of the JP Morgan Global Healthcare Conference

Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced a business update for the fourth...